Literature DB >> 16772392

Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis.

P Kelleher1, A Goodsall, A Mulgirigama, H Kunst, D C Henderson, R Wilson, A Newman-Taylor, M Levin.   

Abstract

Infection by Aspergillus species causes a wide spectrum of pulmonary disease in humans. In two patients with semi-invasive Aspergillus-induced lung disease, significantly reduced levels of interferon-gamma secretion by peripheral blood mononuclear cells were found after in vitro stimulation with the T-cell mitogen phytohaemagglutinin. Despite anti-fungal therapy, both patients exhibited progressive disease, and adjunctive interferon-gamma therapy was associated with significant clinical improvement. The data suggest that impaired production of interferon-gamma can be seen in patients with chronic pulmonary aspergillosis. Adjunctive cytokine therapy with interferon-gamma may be useful in patients with progressive disease despite adequate anti-fungal therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772392     DOI: 10.1183/09031936.06.00021705

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis.

Authors:  David W Denning; Alex Pleuvry; Donald C Cole
Journal:  Bull World Health Organ       Date:  2011-09-27       Impact factor: 9.408

Review 2.  Cytokines and the regulation of fungus-specific CD4 T cell differentiation.

Authors:  Vanessa Espinosa; Amariliz Rivera
Journal:  Cytokine       Date:  2011-11-30       Impact factor: 3.861

Review 3.  Adaptive immunity to fungi.

Authors:  Akash Verma; Marcel Wüthrich; George Deepe; Bruce Klein
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

4.  Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis.

Authors:  Stacy J Park; Molly A Hughes; Marie Burdick; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 5.  Clinical implications of interferon-γ genetic and epigenetic variants.

Authors:  Nicola L D Smith; David W Denning
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

6.  Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.

Authors:  Pappanaicken R Kumaresan; Pallavi R Manuri; Nathaniel D Albert; Sourindra Maiti; Harjeet Singh; Tiejuan Mi; Jason Roszik; Brian Rabinovich; Simon Olivares; Janani Krishnamurthy; Ling Zhang; Amer M Najjar; M Helen Huls; Dean A Lee; Richard E Champlin; Dimitrios P Kontoyiannis; Laurence J N Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

7.  Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.

Authors:  Corine E Delsing; Mark S Gresnigt; Jenneke Leentjens; Frank Preijers; Florence Allantaz Frager; Matthijs Kox; Guillaume Monneret; Fabienne Venet; Chantal P Bleeker-Rovers; Frank L van de Veerdonk; Peter Pickkers; Alexandre Pachot; Bart Jan Kullberg; Mihai G Netea
Journal:  BMC Infect Dis       Date:  2014-03-26       Impact factor: 3.090

Review 8.  Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases.

Authors:  Sharada Ravikumar; Mar Soe Win; Louis Yi Ann Chai
Journal:  Front Microbiol       Date:  2015-11-26       Impact factor: 5.640

9.  A novel insight into the immunologic basis of chronic granulomatous invasive fungal rhinosinusitis.

Authors:  William Rae; Rainer Doffinger; Fenella Shelton; Eleanor Sproson; Hasnaa Ismail-Koch; Valerie J Lund; Philip G Harries; Efrem Eren; Rami J Salib
Journal:  Allergy Rhinol (Providence)       Date:  2016-01

10.  Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis.

Authors:  Felix Bongomin; Chris Harris; Philip Foden; Chris Kosmidis; David W Denning
Journal:  J Fungi (Basel)       Date:  2017-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.